Paloma Partners’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Paloma Partners’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,076	Closed	-$254K	–	2018
2018 Q2	$254K	Buy	+3,076	New	+$297K	﹤0.01%	1359
2017 Q1	–	Sell	-355	Closed	-$33K	–	2290
2016 Q4	$33K	Buy	+355	New	+$33.9K	﹤0.01%	1937

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return

Paloma Partners's VBIV Position: Q3 2018 in Review

Paloma Partners sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2018, closing a stake of 3,076 shares — an estimated $254K sold.

Paloma Partners first reported a position in VBIV in Q4 2016 and held it in 2 quarters. The position peaked at $254K in Q2 2018. 40 funds tracked by Wall St. Rank hold VBIV as of Q3 2018.

Paloma Partners reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2018 after selling out during the quarter.
Paloma Partners sold 3,076 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2018, an estimated $254K.
Paloma Partners first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2016 and held it in 2 quarters.
Paloma Partners's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $254K in Q2 2018.
40 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.